Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments

por Geethakumari, Praveen Ramakrishnan, Ramasamy, Dheepthi Perumal, Dholaria, Bhagirathbhai, Berdeja, Jesús, Kansagra, Ankit
Publicado 2021

Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy

por Flinn, Ian W., Erter, Jack, Daniel, Davey B., Mace, Joseph R., Berdeja, Jesus G.
Publicado 2019

P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.

por Vesole, David H., Berdeja, Jesus, Matous, Jeffrey, Trudel, Suzanne, Schade, Henning, Munster, Pamela, Berkeley, Savannah, Sun, Benjamin, Martin, Tom
Publicado 2023

A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia

por Donnellan, William, Berdeja, Jesus G., Shipley, Diana, Arrowsmith, Edward R., Wright, David, Lunin, Scott, Brown, Richard, Essell, James H., Flinn, Ian W.
Publicado 2017

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study

por Biran, Noa, Siegel, David, Berdeja, Jesus G., Raje, Noopur, Cornell, Robert Frank, Alsina, Melissa, Kovacsovics, Tibor, Fang, Belle, Kimball, Amy S., Landgren, Ola
Publicado 2019

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma

por Derman, Benjamin A., Zonder, Jeffrey, Reece, Donna, Cole, Craig, Berdeja, Jesus, Stefka, Andrew T., Major, Ajay, Kin, Andrew, Griffith, Kent, Jasielec, Jagoda, Jakubowiak, Andrzej J.
Publicado 2023

A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion coh...

por Berdeja, Jesus G., Gregory, Tara K., Faber, Edward A., Hart, Lowell L., Mace, Joseph R., Arrowsmith, Edward R., Flinn, Ian W., Matous, Jeffrey V.
Publicado 2021

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase...

por Berdeja, Jesus, Jagannath, Sundar, Zonder, Jeffrey, Badros, Ashraf, Kaufman, Jonathan L., Manges, Robert, Gupta, Manish, Tendolkar, Amol, Lynch, Mark, Bleickardt, Eric, Paliwal, Prashni, Vij, Ravi
Publicado 2015

A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma

por Alsina, Melissa, Landgren, Ola, Raje, Noopur, Niesvizky, Ruben, Bensinger, William I., Berdeja, Jesus G., Kovacsovics, Tibor, Vesole, David H., Fang, Belle, Kimball, Amy S., Siegel, David S.
Publicado 2020

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

por Rowinsky, Eric K., Paner, Agne, Berdeja, Jesus G., Paba-Prada, Claudia, Venugopal, Parameswaran, Porkka, Kimmo, Gullbo, Joachim, Linder, Stig, Loskog, Angelica, Richardson, Paul G., Landgren, Ola
Publicado 2020

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis

por Gupta, Neeraj, Hanley, Michael J., Harvey, R. Donald, Badros, Ashraf, Lipe, Brea, Kukreti, Vishal, Berdeja, Jesus, Yang, Huyuan, Hui, Ai‐Min, Qian, Mark, Zhang, Xiaoquan, Venkatakrishnan, Karthik, Chari, Ajai
Publicado 2016

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACT...

por Lonial, Sagar, Quach, Hang, Dimopoulos, Meletios A., Rodríguez-Otero, Paula, Berdeja, Jesus, Richardson, Paul, Kyada, Margee, Chu, Shuyu, Chen, Min, Abad, Patricia, Morando, Juliane, van de Donk, Niels W.C.J.
Publicado 2023

P932: PATIENT PERSPECTIVES ON BCMA-TARGETED THERAPIES FOR MULTIPLE MYELOMA: A SURVEY CONDUCTED IN A PATIENT ADVOCACY GROUP

por Hydren, Jay R., Lin, Dee, Arturo Hurtado, Jorge, Sweeney, Nathan W., Wu, Bingcao, Gries, Katharine, Kim, Nina, Patel, Saurabh, Sborov, Douglas W., Berdeja, Jesus, Anderson, Larry D., Stephen Huo, Jinhai, Ahlstrom, Jennifer M.
Publicado 2023

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

por Kelly, Kevin R., Shea, Thomas C., Goy, André, Berdeja, Jesus G., Reeder, Craig B., McDonagh, Kevin T., Zhou, Xiaofei, Danaee, Hadi, Liu, Hua, Ecsedy, Jeffrey A., Niu, Huifeng, Benaim, Ely, Padmanabhan Iyer, Swaminathan
Publicado 2013

S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FRO...

por Bal, Susan, Berdeja, Jesus, Htut, Myo, Kocoglu, Mehmet, Gregory, Tara, Anderson, Larry D., Rossi, Adriana, Egan, Daniel, Costa, Luciano, Kelly, Lisa, Ziyad, Safiyyah, Hu, Hongxiang, Chen, Yanping, Kaeding, Allison J., Burgess, Michael, Hege, Kristen, Nadeem, Omar
Publicado 2023

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

por Kumar, Shaji K., Berdeja, Jesus G., Niesvizky, Ruben, Lonial, Sagar, Laubach, Jacob P., Hamadani, Mehdi, Stewart, A. Keith, Hari, Parameswaran, Roy, Vivek, Vescio, Robert, Kaufman, Jonathan L., Berg, Deborah, Liao, Eileen, Rajkumar, S. Vincent, Richardson, Paul G.
Publicado 2019

Once‐weekly (70 mg/m(2)) vs twice‐weekly (56 mg/m(2)) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W...

por Moreau, Philippe, Stewart, Keith A., Dimopoulos, Meletios, Siegel, David, Facon, Thierry, Berenson, James, Raje, Noopur, Berdeja, Jesus G., Orlowski, Robert Z., Yang, Hui, Ma, Haijun, Klippel, Zandra, Zahlten‐Kumeli, Anita, Mezzi, Khalid, Iskander, Karim, Mateos, Maria‐Victoria
Publicado 2020

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the...

por Weisel, Katja, Martin, Thomas, Krishnan, Amrita, Jagannath, Sundar, Londhe, Anil, Nair, Sandhya, Diels, Joris, Vogel, Martin, Schecter, Jordan M., Banerjee, Arnob, Berdeja, Jesus G., Nesheiwat, Tonia, Garrett, Ashraf, Qi, Keqin, Valluri, Satish, Usmani, Saad Z., Yong, Kwee
Publicado 2021

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma

por Krishnan, Amrita, Kapoor, Prashant, Palmer, Joycelynne M., Tsai, Ni-Chun, Kumar, Shaji, Lonial, Sagar, Htut, Myo, Karanes, Chatchada, Nathwani, Nitya, Rosenzweig, Michael, Sahebi, Firoozeh, Somlo, George, Duarte, Lupe, Sanchez, James F., Auclair, Daniel, Forman, Stephen J., Berdeja., Jesus G.
Publicado 2018

P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF...

por Bahlis, Nizar J, Samaras, Christy, Reece, Donna, Sebag, Michael, Matous, Jeffrey, Berdeja, Jesus, Shustik, Jesse, Schiller, Gary, Ganguly, Siddhartha, Song, Kevin, Seet, Christopher S., Acosta-Rivera, Mirelis, Quick, Donald, Anz, Bertrand, Fonseca, Gustavo, Flores, Unicel-Anne, Liu, Hongjuan, Gentili, Christian, Siegel, David
Publicado 2023